Please login to the form below

Not currently logged in
Email:
Password:

Dr Malte Peters joins MorphoSys

He succeeds Dr Arndt Schottelius as chief development officer

MorphoSys Dr Malte PetersGermany-based therapeutic antibodies specialist MorphoSys has appointed Dr Malte Peters as its new chief development officer, succeeding Dr Arndt Schottelius from 1 March.

Dr Peters joins MorphoSys from Sandoz, where he served as global head of clinical development in its biopharmaceuticals business unit.

Prior to this, he was Novartis' clinical head of oncology translational medicine and head of its Basel and East Hanover sites, and served as head of translational research and pharmacogenomics at Merck KGaA.

During this time he also held teaching appointments in internal medicines and biochemistry at the University of Mainz, in Germany.

Dr Gerald Möller, chairman of MorphoSys' supervisory board, said: “Dr Peters is an ideal addition to the management board of MorphoSys at this stage of the company's growth.

“Drawing on his deep operational and medical experience in oncology and immunology, he will focus his efforts on the development of our clinical and pre-clinical programmes, the most valuable assets driving out future growth.”

17th January 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Tapping the potential of rare diseases: A journey into uncharted territory
...
The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published...
NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...

Infographics